---
title: "CR Sanjiu: CHINARES PHARMA's pediatric tranquilizer and brain supplement granules have received implied approval for clinical trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/266477167.md"
description: "China Resources Pharmaceutical announced that its subsidiary, CR Sanjiu, has obtained implied permission for clinical trials of its pediatric calming and brain-nourishing granules. This product was jointly developed by CR Sanjiu, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen Institute for Drug Inspection and Research, and Shenzhen Traditional Chinese Medicine Manufacturing Innovation Center. It is classified as a Category 1.1 new drug in traditional Chinese medicine, intended for children with tic disorders due to spleen deficiency and phlegm accumulation, as well as wind-phlegm disturbance. The company expects that obtaining this implied permission for clinical trials will help further enrich its product line and enhance the market competitiveness of its products"
datetime: "2025-11-19T04:25:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/266477167.md)
  - [en](https://longbridge.com/en/news/266477167.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/266477167.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/266477167.md) | [繁體中文](https://longbridge.com/zh-HK/news/266477167.md)


# CR Sanjiu: CHINARES PHARMA's pediatric tranquilizer and brain supplement granules have received implied approval for clinical trials

China Resources Pharmaceutical (03320.HK) announced that its subsidiary China Resources Sanjiu's pediatric calming and brain-nourishing granules have obtained implied approval for clinical trials.

This product was jointly developed by China Resources Sanjiu, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen Institute for Drug Inspection and Research, and Shenzhen Traditional Chinese Medicine Manufacturing Innovation Center. It is classified as a new drug of Type 1.1 in traditional Chinese medicine, intended for children with tic disorders due to spleen deficiency and phlegm accumulation, as well as wind-phlegm disturbance. The company expects that obtaining this implied approval for clinical trials will help further enrich its product line and enhance the market competitiveness of its products

### Related Stocks

- [CR Sanjiu (000999.CN)](https://longbridge.com/en/quote/000999.CN.md)
- [CHINARES PHARMA (03320.HK)](https://longbridge.com/en/quote/03320.HK.md)

## Related News & Research

- [China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025](https://longbridge.com/en/news/275124956.md)
- [CR Sanjiu Reports Revenue Growth Amid Profit Decline in 2025 Q3](https://longbridge.com/en/news/262605977.md)
- [89 Arrested In Florida Human Trafficking Operation, Sheriff's Office Says](https://longbridge.com/en/news/278565022.md)
- [Record Childhood Obesity Surge Puts MAHA Health Goals In Focus](https://longbridge.com/en/news/278540530.md)
- [Ultra-processed foods may lead to anxiety, hyperactivity in toddlers](https://longbridge.com/en/news/278508858.md)